• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Logo
  • COVID-19 Resource Center
  • Categories
    • Feature
    • Cardiology trends
    • Cardiology research news
    • Conference coverage
    • Consensus reports & Position papers
    • Resources for Cardiology Professionals
    • COVID-19 Resource Center
  • Videos
  • Cardiology Best Practices

Cardiology Update

The latest trends and advancements made in cardiology research.

SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms

December 21, 2020

Reading Time: 3 minutes

The phenomenon of non-adherence to statin therapy is well known. Reasons for discontinuation include elevated hepatic or muscular enzymes, neurological symptoms, and muscular symptoms collectively referred to as statin-associated muscle symptoms (SAMS).1 SAMS seems to occur less frequently in randomized control trials than in observational studies. These results suggest that SAMS may be attributable to other causes than the pharmacological effects of the statin – including the nocebo effect2.

Clinicians are first encouraged to rule out factors associated with an increased risk of statin intolerance.1 In addition, the likelihood of causality should be carefully considered based on regional distribution and characteristics of the complaint1. Finally, the clinician must ascertain that symptoms began within 4 weeks of initiating the statin. If so, the next step is to implement a dechallenge – rechallenge protocol. This involves withdrawal of the drug for a period of 4 weeks. Symptoms are expected to cease if the statin is the true cause for the SAMS. Next, the statin is re-initiated, and the patient is monitored for recurrence of the same symptoms.

Researchers from Imperial College London provided new insight into SAMS in their correspondence to New England Journal of Medicine.2 They designed a n-of-1 trial of atorvastatin, a placebo, or no treatment to evaluate side effects (Clinical Trials.gov: NCT02668016). A total of 60 patients who had previously discontinued statin therapy due to SAMS were enrolled in the trial. Each participant received four bottles containing a month’s supply of atorvastatin, four bottles containing a month’s supply of a placebo, and four empty bottles. Patients consumed bottle contents for one month at a time in accordance with a randomly generated sequence. They reported any perceived muscular symptoms, including severity.

The primary end point was the “nocebo ratio.” This ratio’s numerator is symptom intensity with placebo minus the symptom intensity with neither statin nor placebo. The denominator is symptom intensity with a statin minus the symptom intensity with neither statin nor placebo. After pooling individual patient data, the nocebo ratio was calculated to be 0.90.

Symptom severity was rated from 0 (no symptoms at all) to 100 (worst imaginable). Among all 60 patients, the mean symptom intensity was 8.0 during no-tablet months, 15.4 during placebo months, and 16.3 during statin months.

Patient expectations of statin treatment

In patients who had discontinued their statins due to SAMS, 90% of the symptoms reported while taking the statin were also reported with taking the placebo (= nocebo effect). Of the 60 participants in the trial, half (30) were able to successfully restart statins. Four others planned to do so, and one was uncontactable.

The remaining 25 who were off statins did not plan to restart them. Of these 25, 18 were still hesitant due to side effects. Four others reported that their cholesterol levels had improved such that they no longer required a statin. One stated that their cholesterol level was unresponsive to a statin. One other had received a new diagnosis of a progressive neurodegenerative disorder. Finally, one reported simply that they were “too old” to restart a statin.

Interestingly among all 60 patients, the mean symptom intensity was 8.0 during no-tablet months (95% CI, 4.7 to 11.3), 15.4 during placebo months (95% CI, 12.1 to 18.7; P<0.001 relative to no-tablet months), and 16.3 during statin months (95% CI, 13.0 to 19.6; P<0.001 relative to no-tablet months. When symptom intensity was compared between statin and placebo months, there was no significant difference (P=0.39). Thus, many patients demonstrated a nocebo effect whereby their symptoms were likely the result psychological impact perhaps due to a negative expectation of statin treatment.

For more cardiology research news, join Cardiology Update on Facebook, Twitter, LinkedIn or Instagram.

Get our free eBook, Cardiology Best Practices, for a comprehensive look at the top position papers, consensus reports and more cardiology news important for daily practice.

Author: Kelly Schoonderwoerd

Reference

  1. Stulc T et al. Curr Atheroscler Rep 2015; 17, 69.
  2. Pedro-Botet J et al. Expert Opin Drug Saf 2019 Jul; 18(7), 573-579.
  3. Wood F et al. NEJM 2020; 383:2182-2184.


Check Out Related Articles

  • Top 10 highlights of ESC Congress 2020Top 10 highlights of ESC Congress 2020
  • Role of iron deficiency in chronic heart failureRole of iron deficiency in chronic heart failure
  • Global consensus on CTO-PCI best practicesGlobal consensus on CTO-PCI best practices

Primary Sidebar

Cardiology News Highlights

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Most featured

Statin therapy: clinical benefits and potential risks

Statin therapies prevent both primary and secondary cardiovascular disease.However, long term safety … Continue Reading about Statin therapy: clinical benefits and potential risks

Cardiology Conferences 2021

Top Cardiology Conferences 2021

With the COVID-19 worldwide pandemic, conferences and congresses planned for 2020 converted to … Continue Reading about Top Cardiology Conferences 2021

AHA 2020 Highlights

Top 10 Highlights of AHA 2020 Congress

The American Heart Association (AHA) 2020 congress took place virtually this year, from November 13 … Continue Reading about Top 10 Highlights of AHA 2020 Congress

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Footer

Cardiology Update

Providing up-to-date developments in the field of cardiology in a clear and concise manner. All articles are written by professional medical journalists and subsequently reviewed by our editorial board. Cardiology Update provides breaking news, that matter to healthcare professionals in the field of cardiology. Subscribe for free to keep up with cardiology news updated regularly.

Learn More About Us

Contact Us

Recent

  • Top Cardiology Conferences 2021
  • SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
  • Top 10 Highlights of AHA 2020 Congress
  • Thromboembolism in COVID-19 patients despite thromboprophylaxis
  • Top 10 highlights of TCT 2020 Congress

Search

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Terms & Conditions | Privacy | Disclaimer
© Clinicalinx B.V. All rights reserved. Postbus 2278, 1000 CG Amsterdam

We use cookies to provide the services and features offered on our website, and to improve our user experience. Learn more Ok
Privacy & Cookies Policy
Necessary Always Enabled